Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02270177
Other study ID # 2009/1430 REK sør-øst
Secondary ID FAS nr: 692HST95
Status Completed
Phase N/A
First received October 2, 2014
Last updated June 13, 2016
Start date September 2012
Est. completion date June 2016

Study information

Verified date May 2016
Source University Hospital of North Norway
Contact n/a
Is FDA regulated No
Health authority Norway:National Committee for Medical and Health Research Ethics
Study type Interventional

Clinical Trial Summary

Headache is a frequent cause of visits to the GPs office, and the investigators have previously shown that this group accounts for about 20 % of patients referred to a general neurologic outpatient clinic.

To our knowledge, no previous study has investigated whether headache consultation through telemedicine provides equal health care outcomes compared to regular visit to the neurologist. If that's the case, a modern interactive health care system may give simpler and cheaper services for patients, saving travelling costs and community expenses. It may possibly also lead to reduced waiting lists, earlier diagnosis and treatment.

This is an open-labeled randomized non-inferiority trial of headache patients referred to a neurologic clinic in North-Norway. The aim of this study is to determine whether video consultations are non-inferior to regular consultations in diagnosing and treating primary headaches. The null hypothesis is that there is no difference in patient satisfaction between the two groups. The outcome is assessed 3 and 12 months after the neurologic consultation.

Participants will be allocated to either a telemedicine consultation or a regular consultation at the neurologic outpatient clinic in the University Hospital of North-Norway, Tromsø. Both groups will undergo a structured and detailed interview to clarify the diagnosis and establish appropriate treatment. To ensure the best possible representation in the population, our goal is to include at least 70% of all the referred patients that meet the criteria for participation. The randomizations are made through a centralized 8-16 phone line to the research-department in Tromsø, at the University Hospital of North-Norway.

Both primary and secondary endpoints will be assessed in questionnaires sent three and 12 months after the consultation. In addition, the quality of the physicians` referrals and calculations of cost savings by using telemedicine will be evaluated.

The patients' informed consent will always be obtained before data collection. Patients are able to withdraw from the study at any time. Withdrawal will not affect the treatment or follow up. Local research ethics committee (REC) has approved the study.


Description:

Epidemiological research shows that over half of Europe's population suffers from headache. Approximately 11% of the population suffers from migraine, over half of the population have tension-type headache, and 4% have chronic daily headaches. There is clear evidence that headaches, and especially migraines, are under- or misdiagnosed. Headache is a frequent cause of visits to the GPs office, and we have previously shown that this group accounts for about 20 % of patients referred to a general neurologic outpatient clinic.

To our knowledge, no previous studies have investigated whether headache consultations through telemedicine provides equal health care outcomes compared to regular visits to the neurologist. If that's the case, a modern interactive health care system may give simpler and cheaper services for patients, saving traveling costs and community expenses. It may possibly also lead to reduced waiting lists, earlier diagnosis and treatment.

This is an open-label randomized non-inferiority study of headache patients referred to our neurologic outpatient clinic. The aim of this study is to determine if video consultations are non-inferior to regular consultations in diagnosing and treating primary headaches. The null hypothesis is that there is no difference in patient satisfaction between the two groups. The outcome is assessed 3 and 12 months after the neurologic consultation. We will allocate participants to either a telemedicine consultation or a regular consultation at the neurologic outpatient clinic in the University Hospital of North-Norway, Tromsø. Both groups will undergo a structured and detailed interview to clarify the diagnosis and establish appropriate treatment. All diagnoses are given by the most up to date version of The International Classification of Headache Disorders (ICHD). We will strive continuously to include all patients who meet the inclusion and exclusion criteria. To ensure the best possible representation in the population, our goal is to include at least 70% of all the referred patients that meet the criteria for participation in this study. The randomizations are made through a centralized 8-16 phone line to the research-department in Tromsø, at the University Hospital of North-Norway.

We will gather the primary and secondary endpoints from the recruited participants by questionnaires sent three and 12 months after the consultation. In addition, we are going to investigate the quality of the physicians` referrals, peoples` use of medications, alternative therapies as well as calculations of cost savings by using telemedicine.

The patients' informed consent will always be obtained before data collection. Patients are able to withdraw from the study at any time. Withdrawal will not affect the treatment or follow up. Local research ethics committee (REC) has approved the study.


Recruitment information / eligibility

Status Completed
Enrollment 402
Est. completion date June 2016
Est. primary completion date June 2016
Accepts healthy volunteers No
Gender Both
Age group 16 Years to 65 Years
Eligibility Inclusion Criteria:

- Females and males =16 and =65 years of age

- Referred to a neurologist for headache

- No red flags (defined) suggestive of a secondary cause? No known underlying causes of headaches (secondary headaches) according to established criteria

- Referred for diagnostic clarification and / or treatment

- Waiting time = 4 months from the date of the referral

- speaking Norwegian language

Exclusion Criteria:

- Age <16 years or > 65 years of age

- Known underlying cause of the headache or the presence of red flags suggestive of secondary headaches.

- Examined by a neurologist for headaches in a period of 2 years before referral

- Waited longer than 4 months from the date of referral

- Non-Norwegian speaker

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research


Related Conditions & MeSH terms


Intervention

Other:
Telemedicine, videoconsultation
We are investigating the use of videoconsultations (through telemedicine technology) in patients with primary headaches.

Locations

Country Name City State
Norway Department of Neurology, University Hospital of North Norway Tromsø Troms

Sponsors (2)

Lead Sponsor Collaborator
University Hospital of North Norway University of Tromso

Country where clinical trial is conducted

Norway, 

References & Publications (11)

Bekkelund SI, Albretsen C. Evaluation of referrals from general practice to a neurological department. Fam Pract. 2002 Jun;19(3):297-9. — View Citation

Bekkelund SI, Salvesen R. Is uncertain diagnosis a more frequent reason for referring migraine patients to neurologist than other headache syndromes? Eur J Neurol. 2006 Dec;13(12):1370-3. — View Citation

Bekkelund SI, Salvesen R. Patient satisfaction with a neurological specialist consultation for headache. Scand J Prim Health Care. 2002 Sep;20(3):157-60. — View Citation

Bekkelund SI, Salvesen R; North Norway Headache Study (NNHS). Are headache patients who initiate their referral to a neurologist satisfied with the consultation? A population study of 927 patients--the North Norway Headache Study (NNHS). Fam Pract. 2001 Oct;18(5):524-7. — View Citation

Cottrell C, Drew J, Gibson J, Holroyd K, O'Donnell F. Feasibility assessment of telephone-administered behavioral treatment for adolescent migraine. Headache. 2007 Oct;47(9):1293-302. — View Citation

Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004;24 Suppl 1:9-160. — View Citation

Pryse-Phillips W. Evaluating migraine disability: the headache impact test instrument in context. Can J Neurol Sci. 2002 Jun;29 Suppl 2:S11-5. Review. — View Citation

Salvesen R, Bekkelund SI. Aspects of referral care for headache associated with improvement. Headache. 2003 Jul-Aug;43(7):779-83. — View Citation

Stovner LJ, Andree C. Prevalence of headache in Europe: a review for the Eurolight project. J Headache Pain. 2010 Aug;11(4):289-99. doi: 10.1007/s10194-010-0217-0. Epub 2010 May 16. Review. — View Citation

Stovner LJ, Andrée C; Eurolight Steering Committee. Impact of headache in Europe: a review for the Eurolight project. J Headache Pain. 2008 Jun;9(3):139-46. doi: 10.1007/s10194-008-0038-6. Epub 2008 Apr 17. Review. — View Citation

Stovner LJ, Zwart JA, Hagen K, Terwindt GM, Pascual J. Epidemiology of headache in Europe. Eur J Neurol. 2006 Apr;13(4):333-45. Review. — View Citation

* Note: There are 11 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Other Estimation of travelling distances to the neurologic outpatient clinic travelling distances in kilometers travelling distance in kilometers for the neurologic consultation (telemedicine versus regular consultation) and the average travelling distance to the GP during the consecutive 11 months No
Other Expenses saved by using telemedicine Evaluation of the expenses associated with telemedicine compared to regular consultations (travelling expensis, lost earnings, days away from work, Expenses (travelling, lost income and days absent from work) for the neurologic consultation and the average expenses for GP-consultations during the consecutive 11 months No
Other Number of headache days and headaches Change in number of headache days per month and number of headahces per month change in number of headaches from baseline, at 3 months and 12 months No
Other Change in headache feature Is the headahce bether, worse or the same. Is the headahce more intens, less intens or unchanged. Change in headache features from baseline, after 3 months and 12 months No
Primary Number of satisfied participants Are you satisfied with the consultation? Yes/No change from baseline at 3 months and 12 months No
Secondary VAS satisfaction rating scale Visual analog satisfaction scale 0-10, where 0 = least satisfied and 10 = most satisfied 12 months No
Secondary VAS pain scale Headache measured by a visual analog scale 0-10, 0= no pain, 10=worst pain changes from baseline in VAS at 3 months and 12 months No
Secondary HIT-6 Headache impact test Changes from baseline in HIT 6 at 3 months and 12 months No
Secondary Job situation/occupation Job situation/occupation changes from baseline in job situation at 3 months and 12 months No
Secondary numbers of consultations during follow up numbers of GP-consultations, hospital consultations and admissions numbers of consultations from baseline and after 12 months No
Secondary number of pain killers, triptans and other medications for headache number of medications for headache at baseline, after 3 months and after 12 months No
Secondary headache diagnosis Headache diagnosis after IHS criteria at baseline, after 3 months and 12 months No
See also
  Status Clinical Trial Phase
Completed NCT00956969 - Stress Management for Chronic Headaches N/A
Completed NCT00475189 - Study of Loestrin 24(24 Days of "Real" Pills) Fe Versus Loestrin 1/20 (21 "Real" Pills) N/A
Terminated NCT02638506 - RCT Evaluating Intranasal Fentanyl in the Pain Management of Children With Headaches Phase 4
Completed NCT00484029 - Nasal Carbon Dioxide (CO2)for the Treatment of Temporomandibular Disorders (TMD)Related Pain Phase 2
Completed NCT01667679 - Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Phase 3
Completed NCT00921453 - Tailored Internet Information Supply for Patients - Part 2 N/A
Completed NCT00067249 - Women's Use of Alternative Medicine: A Multiethnic Study N/A